

**CLONING, EXPRESSION AND IMMUNOGENICITY OF RECOMBINANT  
BACILLE CALMETTE-GUERIN (BCG) CONTAINING T AND B CELL  
EPITOPES OF *Mycobacterium tuberculosis***

**by**

**ROHIMAH BINTI MOHAMUD**

**Thesis submitted in fulfillment of the  
requirements for the degree  
of Master of Science**

*Submitted to:*

**UNIVERSITI SAINS MALAYSIA**

**2008**

## DEDICATIONS

This thesis is specially dedicated to:

**My beloved husband, Mohd. Shamsul Hisham bin Mat Hassan Latfi**  
**My daughters, Fatin Shahirah, Fatin Shakirah and Alissa Shafiyah**  
**My parents, Mohamud bin Awg. Kechik and Siti Bidah binti Loman**

Thank you for your love, patience and encouragement.

May Allah bless you all...

## ACKNOWLEDGEMENTS

In the name of Allah, the Most Generous and the Most Merciful. All praise are due to Allah for His guidance and peace that give me the ingredients of success.

I wish to acknowledge several people who have been involved directly or indirectly during this research project.

Above all, I would like to thank my supervisor, Prof. Norazmi Mohd. Nor for his support, excellent guidance and supervision throughout the experimental work and also during the writing of this thesis. His guidance and encouragement are greatly appreciated.

I would also like to express my gratitude to my co-supervisor, Dr. Rapeah Suppian for the encouragement, kind guidance and helpful discussions during this study.

I would also like to thank Assoc. Prof. Dr. Nik Soriani Yaacob and Dr. Shaharum Shamsuddin for advice, guidance and overall comments.

I would like to extend my thanks to my friends and colleagues in the laboratory especially, K. Maryam, Asma, Teo, Rafeezul, Zila, Kenny, Boonyin, Syam, K. Ayu, K. La, Fatma, Amir and Wong Vic Cern. Not to forget, my friends in ZFZ and SS group, Eza, Zura, Abdah, K. Su, K. Nurul, Aniek, Yuni, Tini, Bad, Azan, Kak Lin, Venu and Nida. Thank you for both your friendship and assistance during the course of this study.

A special thanks to my parents, Mohamud and Siti Bidah, my brothers and sisters for their support and guidance during this work. Not to forget to my parents-in-law, Hj. Mat Hassan Latfi and Hjh. Rofiah, my brothers- and sister-in-law for their support and encouragement. Finally I wish to acknowledge the greatest support, love and encouragement from my beloved husband, Mohd. Shamsul Hisham for his love and

patience; thanks for being there and encouraging me when needed. My appreciation also goes to my beloved daughters, Fatin Shahirah, Fatin Shakirah and Alissa Shafiyah; they always make me happy.

There are many people that I would like to thank for contributing directly or indirectly to this study. I cannot mention you all so I hope you feel my gratitude.

patience; thanks for being there and encouraging me when needed. My appreciation also goes to my beloved daughters, Fatin Shahirah, Fatin Shakirah and Alissa Shafiyah; they always make me happy.

There are many people that I would like to thank for contributing directly or indirectly to this study. I cannot mention you all so I hope you feel my gratitude.

# TABLE OF CONTENTS

<b>ACKNOWLEDGEMENTS</b>	iii
<b>TABLE OF CONTENTS</b>	v
<b>LIST OF TABLES</b>	xi
<b>LIST OF FIGURES</b>	xii
<b>LIST OF ABBREVIATIONS</b>	xiv
<b>LIST OF APPENDICES</b>	xvi
<b>ABSTRACT</b>	xvii
<b>ABSTRAK</b>	xix
<b>CHAPTER ONE : INTRODUCTION</b>	
1.1 Background	1
1.2 History of TB	1
1.3 Global incidence of TB	1
1.4 <i>M. tuberculosis</i>	4
1.5 Transmission of <i>M. tuberculosis</i>	6
1.6 Pathogenesis of <i>M. tuberculosis</i>	6
1.7 Overview of TB disease	8
1.8 TB in Malaysia	8
1.9 TB in children	9
1.10 Symptoms of TB	10
1.11 Diagnosis of TB	10
1.11.1 Chest radiograph	10
1.11.2 Sputum test	11
1.11.3 Mantoux tuberculin skin test (TST)	11
1.11.4 Nucleic acid amplification (NAA) test	11
1.11.5 Interferon-gamma (IFN- $\gamma$ ) assay	12
1.12 Treatment of TB	12
1.13 Immunity to TB	13
1.13.1 Innate immunity	13
1.13.2 Adaptive immunity	15
1.13.2.1 Humoral immune response	15
1.13.2.2 Cellular immune response	16
1.14 Vaccination and memory T cells	18

1.15	BCG	20
	1.15.1 Efficacy and effectiveness of BCG	20
1.16	Development of effective vaccines against TB	21
	1.16.1 Live vaccines	23
	1.16.1.1 Attenuated mycobacteria	23
	1.16.1.2 Recombinant BCG (rBCG)	23
	1.16.2 Non-live vaccines	23
	1.16.2.1 Subunit vaccine	23
	1.16.2.2 DNA vaccine	24
	1.16.3 Prime boost vaccination	24
1.17	Potential candidate antigens of <i>M. tuberculosis</i>	25
	1.17.1 Mtb8.4	25
	1.17.2 Ag85B	25
	1.17.3 ESAT-6	26
	1.17.4 CFP10	26
	1.17.5 MTP40	26
1.18	Justification, objective and research plan	27

## CHAPTER TWO: MATERIALS AND METHODS

2.1	Materials	29
	2.1.1 Mouse strain	29
	2.1.2 Rabbit strain	29
	2.1.3 <i>E. coli</i> strains	29
	2.1.4 Chemicals and reagents	29
	2.1.5 Sterilized, deionised distilled water	34
	2.1.6 Enzymes	34
	2.1.7 Antibodies	34
	2.1.8 Peptides	34
	2.1.9 Primers	34
	2.1.10 Oligonucleotides	34
	2.1.11 Plasmids	34
	2.1.12 Laboratory equipment	43
	2.1.13 Laboratory kits and consumables	43
	2.1.14 Media	43
	2.1.14.1 Luria-Bertani (LB) Broth	43
	2.1.14.2 Luria-Bertani Agar (LA)	43

2.1.14.3	7H9 Broth	43
2.1.14.4	7H11 Agar	47
2.1.14.5	RPMI medium	47
2.1.15	Buffers and solutions	47
2.1.15.1	ABTS substrate for ELISA	47
2.1.15.2	Ammonium chloride/potassium (ACK) lysis buffer (1 x)	47
2.1.15.3	Ammonium persulfate (AP) solution (20 %)	48
2.1.15.4	Ampicillin stock solution (100 mg/ml)	48
2.1.15.5	Blocking buffer for ELISA	48
2.1.15.6	Blocking buffer (5 %) for Western blotting	48
2.1.15.7	CaCl <sub>2</sub> solution (100 mM)	48
2.1.15.8	Coating buffer for ELISA	49
2.1.15.9	Con A solution (1 mg/ml)	49
2.1.15.10	Coomassie blue solution	49
2.1.15.11	Dialysis buffer	49
2.1.15.12	Destaining solution	49
2.1.15.13	Detection solution for Western blotting	50
2.1.15.14	DNA markers	50
2.1.15.15	Elution buffer (buffer D and buffer E)	50
2.1.15.16	Ethanol solution (70 %)	50
2.1.15.17	EtBr solution (10 mg/ml)	50
2.1.15.18	EDTA solution (0.5 M)	50
2.1.15.19	Glycerol solution (10 %)	51
2.1.15.20	Glycerol solution (80 %)	51
2.1.15.21	HEPES solution	51
2.1.15.22	HCl solution (1 M)	51
2.1.15.23	INH solution (10 mg/ml)	51
2.1.15.24	IPTG solution (1 M)	51
2.1.15.25	Loading dye solution	52
2.1.15.26	Kanamycin solution (50 mg/ml)	52
2.1.15.27	Lysis buffer	52
2.1.15.28	MgCl <sub>2</sub> solution (100 mM)	52
2.1.15.29	[methyl-3H] Thymidine solution	52
2.1.15.30	NaOH solution (3 M)	53
2.1.15.31	Perm/ Wash Buffer (1 x)	53



2.1.15.32	PBS solutions	53
2.1.12.33	PMSF solution (100 mM)	53
2.1.12.34	Resolving buffer for SDS-PAGE	53
2.1.12.35	Running buffer for SDS-PAGE	54
2.1.12.36	Sample buffer for SDS-PAGE	54
2.1.12.37	Stacking buffer for SDS-PAGE	54
2.1.12.38	Staining buffer for flow cytometry	54
2.1.12.39	Stop solution for ELISA	54
2.1.12.40	Tris-acetate-EDTA (TAE) stock solution (50 x)	55
2.1.12.41	Tris-base solution (1.5 M) containing 0.4 % SDS	55
2.1.12.42	Tris-EDTA (TE) buffer	55
2.1.12.43	Tris-HCl solution (1.5 M) containing 0.4 % SDS	55
2.1.12.44	Trypan blue solution (0.4 %)	55
2.1.12.45	Towbin transfer buffer	55
2.1.12.46	Washing buffer (buffer C)	56
2.2	Methods	56
2.2.1	Primers and oligonucleotides preparation	56
2.2.2	Synthetic peptide preparation	56
2.2.3	Preparation of Polymerase Chain Reaction (PCR) master mix	56
2.2.4	Preparation of <i>E. coli</i> competent cells	57
2.2.5	Transformation into <i>E. coli</i> competent cells	60
2.2.6	Preparation of BCG competent cell	60
2.2.7	Transformation of DNA into BCG competent cell	61
2.2.8	Determination of colony forming unit (CFU) of BCG/rBCG culture	61
2.2.9	Glycerol stock of <i>E. coli</i>	61
2.2.10	Extraction of plasmid DNA	62
2.2.11	Quantification of DNA	63
2.2.12	DNA ligation	63
2.2.13	A-tailing protocol	63
2.2.14	TOPO <sup>®</sup> cloning reaction	63
2.2.15	PCR screening	66
2.2.16	DNA sequencing	66
2.2.17	Long term storage of DNA products	66
2.2.18	RE digestion	66
2.2.19	Agarose gel electrophoresis	66

2.2.20 DNA extraction from agarose gel	68
2.2.21 Protein analysis	69
2.2.21.1 Protein expression in <i>E. coli</i>	69
2.2.21.1.1 Optimization of incubation time for optimum expression	69
2.2.21.1.2 Preparation of cleared <i>E. coli</i> lysates	69
2.2.21.1.3 Large scale protein production	70
2.2.21.1.4 Purification of 6x-His tagged protein	70
2.2.21.1.5 Protein sample preparation	71
2.2.21.1.6 Resolving and stacking gel preparation	71
2.2.21.1.7 SDS-PAGE	71
2.2.21.1.8 Western blotting	71
2.2.21.1.9 Immunoassay	73
2.2.21.1.10 Dialysis	74
2.2.21.1.11 Quantification of protein concentration	74
2.2.21.2 Protein expression in BCG	74
2.2.22 Polyclonal antibody production	75
2.2.22.1 Immunization of rabbit	75
2.2.22.2 Blood collection from rabbit	75
2.2.23 Immunogenicity study	77
2.2.23.1 Preparation of candidate vaccines and controls for immunization	77
2.2.23.2 Immunization of mice	77
2.2.23.3 Blood collection from mice	77
2.2.23.4 Splenocytes preparation	79
2.2.23.5 Determination of cell concentration	79
2.2.23.6 Cell culture	80
2.2.23.7 LTT	80
2.2.23.8 Intracellular cytokine assay	81
2.2.23.9 Flow cytometry analysis	82
2.2.23.10 ELISA	82
2.2.24 Stability and safety study of rBCG	83
2.2.25 Statistical analysis	83

## **CHAPTER THREE: RESULTS**

3.1	Introduction	84
3.2	Construction of recombinant plasmids	84
3.3	Production of the polyclonal anti-Mtb8.4 antibody	94
3.4	Construction and expression of rBCG	94
3.5	Immunogenicity studies	94
3.5.1	LTT	94
3.5.1.1	LTT of rBCG018-immunized mice	94
3.5.1.2	LTT of rBCG032-immunized mice	102
3.5.2	Antibody response of mice immunized with rBCG	102
3.5.2.1	Total IgG of rBCG018- and rBCG032-immunized mice	105
3.5.2.2	IgG subclasses of rBCG032-immunized mice	105
3.5.3	Detection of intracellular cytokines produced by CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells	105
3.5.3.1	Intracellular cytokines produced by CD4 <sup>+</sup> T cells	108
3.5.3.2	Intracellular cytokines produced by CD8 <sup>+</sup> T cells	108
3.6	Preliminary safety and stability studies	110
		118
	<b>CHAPTER FOUR: DISCUSSION AND CONCLUSION</b>	126
	<b>REFERENCES</b>	156
	<b>LIST OF APPENDICES</b>	

## LIST OF TABLES

2.1	List of chemicals and reagents	30
2.2	List of enzymes	35
2.3	List of antibodies	36
2.4	List of synthetic peptides and antigen	37
2.5	List of primers	38
2.6	List of oligonucleotides used for assembly PCR	39
2.7	Map of plasmid vectors	41
2.8	List of equipment	44
2.9	List of kits and consumables	45
2.10	Composition of a 25 $\mu$ l typical PCR master mix	58
2.11	Composition of 10 $\mu$ l A-tailing PCR	64
2.12	Composition of 6 $\mu$ l TOPO <sup>®</sup> cloning reaction	65
2.13	Composition of 20 $\mu$ l RE digestion	67
2.14	Composition for SDS-PAGE preparation	72
3.1	The synthetic gene cloned into the pCR <sup>®</sup> -2.1 TOPO <sup>®</sup> cloning vector	91
3.2	CFU of rBCG after 2 weeks of incubation	99
3.3	Summary of the fold increase as compared to the BCG-immunized mice group (CD4 <sup>+</sup> )	109
3.4	Summary of the fold increase as compared to the BCG-immunized mice group (CD8 <sup>+</sup> )	111

## LIST OF FIGURES

1.1	TB notification rates in 2001	3
1.2	AFB smear	5
1.3	The chronology of events of <i>M. tuberculosis</i> infection	7
1.4	Vaccine induction of memory T cells in humans	19
1.5	Results of various controlled clinical trials of BCG vaccine	22
1.6	Flow chart of research strategy	28
2.1	Schematic outline of assembly PCR	59
2.2	Production of polyclonal antibody against Mtb8.4	76
2.3	Immunization of mice	78
3.1	Map and sequence of the T cell epitopes, designated as TBvac1.0 Fragment (399bp)	85
3.2	Map and sequence of the T cell epitopes, designated as TBvac2.0 Fragment (264bp)	86
3.3	Map and sequence of the B cell epitopes, designated as TBvac3.0 Fragment (282bp)	87
3.4	Agarose gel electrophoresis showing the product of assembly and amplification of TBvac1.0 Fragment	88
3.5	Agarose gel electrophoresis showing the product of assembly and amplification of TBvac2.0 Fragment	89
3.6	Agarose gel electrophoresis showing the product of amplification of TBvac3.0 Fragment	90
3.7	Construction of the expression vector, pNMN022	92
3.8	Optimization for protein expression	93
3.9	Preparation of lysate for protein expression	95

3.10	SDS-PAGE analysis of purified polyhistidine-tagged TBvac2.0 protein	96
3.11	Construction of the shuttle plasmid, pNMN018 containing TBvac1.0 Fragment and <i>Myco</i> ORI.	97
3.12	Construction of the shuttle plasmid, pNMN032 containing TBvac1.0 Fragment and <i>Myco</i> ORI.	98
3.13	Expression of TBvac1.0 Fragment in BCG	100
3.14	Expression of TBvac3.0 Fragment in BCG	101
3.15	Lymphocyte proliferative response of rBCG018-immunized mice	103
3.16	Lymphocyte proliferative response of rBCG032- immunized mice	104
3.17	Profile of antigen-specific total IgG response against T and B cell epitopes in Balb/c mice	106
3.18	Mean OD of IgG subclasses in mice	107
3.19	Weight of mice 6 weeks after the 2 <sup>nd</sup> booster (n=5)	112
3.20	Weight of organs after 6 weeks following the 2 <sup>nd</sup> booster (n=5)	113
3.21	CFU of rBCG in selected organs of mice 6 weeks after the 2 <sup>nd</sup> booster (n=5)	115
3.22	PCR screening on randomly selected colonies obtained from selected organs of rBCG018-immunized mice	116
3.23	PCR screening on randomly selected colonies obtained from selected organs of rBCG032-immunized mice	117

## LIST OF ABBREVIATIONS

AIDS	Acquired immunodeficiency syndrome
AFB	Acid fast bacillus
Ag85	Antigen 85
APCs	Antigen presenting cells
B.C	Before Century
BCG	Bacille Calmette Guerin
bp	base pair
CD	Cluster of differentiation
CFU	Colony forming unit
CFP	Culture filtrate protein
CTL	Cytotoxic T lymphocyte
CPM	Count per minute
ddH <sub>2</sub> O	Deionised distilled water
DNA	Deoxyribonucleic acid
ETH	Ethambutol
$\gamma\delta$	Gamma delta
HIV	Human Immunodeficiency Virus
IFN	Interferon
IFN- $\gamma$ R	IFN- $\gamma$ Receptor
IL	Interleukin
i.m	Intramuscular
INH	Isoniazid
i.p	Intraperitoneal
kDa	Kilo Dalton
KO	Knock out
LTT	Lymphocytes transformation test
MHC	Major histocompatibility complex
MDR-TB	Multi drug resistant-TB
NAA	Nucleic acid amplification
NK	Natural killer
OD	Optical density
ORF	Open reading frame
PAS	P-aminosalicylic acid
PBMC	Peripheral blood mononuclear cell

PCR	Polymerase chain reaction
PPD	Purified protein derivative
PZA	Pyrazinamide
rBCG	Recombinant bacilli Calmette Guerin
RBC	Red blood cell
RD	Region of difference
RE	Restriction enzyme
RIF	Rifampin
RT	Room temperature
SI	Stimulation index
T <sub>CM</sub>	T central memory
T <sub>EM</sub>	T effector memory
Th	T helper
TB	Tuberculosis
TLR	Toll like receptor
TNF	Tumor necrosis factor
TST	Tuberculin skin test
WHO	World Health Organization



## LIST OF APPENDICES

1.1	Appendix A Cloning of multiple <i>Mycobacterium tuberculosis</i> epitopes in <i>Mycobacterium bovis</i> bacille Calmette-Gúerin (BCG)	156
1.2	Appendix B Expression and Immunogenicity study of recombinant <i>Mycobacterium bovis</i> Bacille Calmette-Gúerin (BCG) expressing tuberculosis epitopes in Balb/c mice	157
1.3	Appendix C A DNA-recombinant BCG prime-boost approach as a potential immunization strategy against tuberculosis	158
1.4	Appendix D Expression and Immunogenicity study of recombinant <i>Mycobacterium bovis</i> Bacille Calmette-Gúerin (BCG) expressing T and B cell epitopes of <i>Mycobacterium tuberculosis</i>	159

**CLONING, EXPRESSION AND IMMUNOGENICITY OF RECOMBINANT BACILLE  
CALMETTE-GUERIN (BCG) CONTAINING T AND B CELL EPITOPES OF  
*Mycobacterium tuberculosis***

**ABSTRACT**

Tuberculosis (TB) remains one of the leading causes of morbidity and mortality in humans. The only TB vaccine currently available is an attenuated strain of *Mycobacterium bovis*, bacille Calmette–Guerin (BCG). However, the efficacy of BCG continues to be debated. The BCG protection against adult pulmonary TB ranged from 0 to 80 % in randomized control trials. In addition, the rising rates of multi-drug resistant *M. tuberculosis* have worsened the situation. Thus, an improved TB vaccine is urgently needed. Recombinant BCG (rBCG) is one of the most potential approaches in evoking the immune response against TB. In this study, two different types of rBCG were constructed: rBCG expressing T cell epitopes from *M. tuberculosis* Ag85B antigens and Mtb8.4 protein (rBCG018) or a combination of the antigens fused to B cell epitopes from ESAT-6, CFP10 and MTP40 proteins (rBCG032). Polyclonal anti-Mtb8.4 was successfully raised in rabbit and subsequently used for rBCG expression. Immunogenicity study of the vaccine constructs were used for immunization of Balb/c mice. Specific IgG response was obtained against the ESAT-6 and CFP10 in the sera of rBCG032-immunized mice. Splenocytes from these mice showed a high response against the Ag85B antigens and the Mtb8.4 protein, whereas splenocytes from rBCG018-immunized mice elicited a lower response against Ag85B epitopes and a high response against Mtb8.4 protein. Mice immunized with the rBCG strains produced a Th1 pattern of response against the T cell epitopes. Six weeks after the final immunization, the rBCG constructs were recovered from spleen, lung, liver and peritoneal washout. The presences of both constructs in the colonies grown from the organ were detected by PCR. In conclusion, the data obtained from this study demonstrates that T and B epitopes expressed in a single rBCG construct induced

appropriate humoral and cellular immune responses against immunogenic epitopes from *M. tuberculosis*.

**PENGLONAN, EKSPRESI DAN IMUNOGENISITI BACILLE CALMETTE-GUERIN  
(BCG) REKOMBINAN YANG MENGANDUNGI EPITOP SEL T DAN B**

*Mycobacterium tuberculosis*

**ABSTRAK**

Tuberkulosis (TB) merupakan salah satu penyakit yang menyebabkan banyak kematian kepada manusia. Terdapat hanya satu vaksin TB pada masa ini iaitu strain yang telah dilemahkan, *Mycobacterium bovis* bacille Calmette–Guèrin (BCG). Bagaimanapun, keberkesanan BCG masih hebat diperdebatkan. Daripada kajian yang dijalankan secara rawak, keberkesanan BCG terhadap penyakit TB pulmonari dalam kalangan orang dewasa didapati di antara 0 hingga 80 %. Tambahan pula, kadar kerintangan drug TB yang sentiasa meningkat merumitkan lagi masalah yang sedia ada. Oleh itu, vaksin yang lebih berkesan terhadap TB sangat diperlukan. BCG rekombinan (rBCG) merupakan salah satu langkah yang berpotensi untuk meningkatkan sistem keimunan terhadap TB. Di dalam kajian ini, dua jenis rBCG telah dihasilkan: rBCG yang mengkodkan epitop sel T daripada *M. tuberculosis* iaitu antigen Ag85B dan protein Mtb8.4 (rBCG018) atau kombinasi antigen-antigen tersebut dengan epitop sel B iaitu ESAT-6, CFP10 dan protein MTP40 (rBCG032). Anti-Mtb8.4 poliklonal telah berjaya dihasilkan di dalam arnab dan seterusnya digunakan dalam ekspresi rBCG. Kajian keimunan terhadap konstruk vaksin ini telah dijalankan di dalam mencit Balb/c. Gerakbalas IgG yang spesifik dapat diperhatikan terhadap epitop ESAT-6 dan CFP10 dalam sera mencit yang diimmunisasi dengan vaksin rBCG032. Splenosit daripada kumpulan mencit ini juga menunjukkan gerakbalas yang tinggi terhadap epitop Ag85B dan protein Mtb8.4. Splenosit mencit yang diimmunisasi dengan vaksin rBCG018 merangsang gerakbalas yang rendah terhadap epitop Ag85B, tetapi menunjukkan tindak balas yang tinggi terhadap protein Mtb8.4. Sel T CD4<sup>+</sup> dan CD8<sup>+</sup> daripada splenosit mencit yang diimmunisasi dengan kedua-dua rBCG menghasilkan gerakbalas Th1 terhadap epitop sel T. Selepas dimunisasi selama 6 minggu, kehadiran

rBCG yang terdapat di dalam limpa, paru-paru, hati dan basuhan peritoneum koloni organ telah dapat dikesan. Sebagai kesimpulan, data yang diperolehi daripada kajian ini menunjukkan bahawa rBCG yang mengkodkan sel T dan B telah berupaya meningkatkan gerakbalas humoral dan sel terhadap epitop-epitop *M. tuberculosis* yang immunogenik.

# CHAPTER ONE

## INTRODUCTION

### 1.1 Background

Tuberculosis (TB) remains one of the leading causes of death worldwide (Frieden *et al.*, 2003). More than one-third of the world's population have been infected with TB and new infections are occurring at a rate of one per second (WHO, 2006).

### 1.2 History of TB

TB has been present in humans since ancient times. *Mycobacterium tuberculosis* was first viewed in 1882 when Robert Koch discovered a special staining technique that allowed identifying the organism and announced the discovery of TB bacillus on 24<sup>th</sup> of March 1882 (Reviewed by Kanai, 1990). The Sanatorium era began after the discovery of the tubercle bacilli by Robert Koch (Reviewed by Bloom and Murray, 1992). In 1982, the first World TB Day was held by World's Health Organization (WHO). Studies have provided evidence for the presence of *M. tuberculosis* complex in ancient skeletal and mummified materials (Crubezy *et al.*, 1998; Haas *et al.*, 2000; Mays *et al.*, 2001; Zink *et al.*, 2001). The deoxyribonucleic acid (DNA) analysis of the tissue samples from Egyptian mummies [2125 Before Century (B.C)] has shown that an original *M. tuberculosis* complex was similar to the recent *M. tuberculosis* (Crubezy *et al.*, 1998; Zink *et al.*, 2003). Brosch *et al.* (2002) reported that *M. africanum*, *M. microti* and *M. bovis* strains diverged from the progenitor of *M. tuberculosis*.

### 1.3 Global incidence of TB

TB is a major health problem of worldwide concern both in developing as well as in industrialized countries. In 2002, almost 9 million new TB cases occurred (WHO,

2006). One out of 6 adults (15-59 years old) who live in developing countries dies from this disease (Murray *et al.*, 1990; Dye *et al.*, 1999) and more than 8 million new cases of TB develop every year (Dye *et al.*, 1999). The number of deaths by TB (3 million people) is higher than the number of those caused by heart disease, cancer or any other infectious agents (Murray *et al.*, 1992). Moreover, more than 90 % of all TB cases and deaths occur in developing countries (Bloom & Murray, 2003; WHO Fact Sheet, 2003). The incidence of TB has increased significantly in areas with high rates of human immunodeficiency virus (HIV) infection, particularly in sub-Saharan Africa. WHO (WHO Fact Sheet, 2000) reported that the TB incidence rates in this area increased three-fold in the 1990s. It is estimated that most people infected with HIV (90 %) are in developing countries, especially in the 20-35 age group. In some areas, 70 % of new TB patients are HIV co-infected (Elliot *et al.*, 1990; De Cock *et al.*, 1992). Worldwide, TB is the most common cause of death among acute immunodepression syndrome (AIDS) patients, killing 1 of every 3 of them.

Besides co-infection with HIV, factors that are related to the high TB burden include homelessness and poverty, increasing number of refugees, reduction of governmental support in TB prevention and lack of treatment programs (Brudney & Dobkin, 1991). Another reason for the rising rate of TB cases is due to the high rate of immigration from countries with a high incidence of TB.

TB is the leading infectious cause of death among people in more than 5 years of age in South-East Asia and accounts for approximately 33 % of all the cases of TB in the world. Within South-East Asia, more than 95 % of cases are found in India, Indonesia, Bangladesh, Thailand, and Myanmar (Murray *et al.*, 1990; Kochi, 1991; Bloom and Murray, 1992). Frieden *et al.* (2003) reported that 80 % of new TB cases occur in 22 high-burden countries (Figure 1.1).




Figure 1.1: TB notification rates in 2001 (Adapted from Frieden *et al.*, 2003).